Wang, Wei-ChunWei-ChunWangFann, Jean Ching-YuanJean Ching-YuanFannRAY-E CHANGJeng, Ya-ChungYa-ChungJengHsu, Chen-YangChen-YangHsuChen, Tony Hsiu HsiTony Hsiu HsiChenLiu, Jin-TanJin-TanLiuYen, Amy Ming-FangAmy Ming-FangYen2021-07-072021-07-072021-060929-6646https://scholars.lib.ntu.edu.tw/handle/123456789/570518Vaccine is supposed to be the most effective means to prevent COVID-19 as it may not only save lives but also reduce productivity loss due to resuming pre-pandemic activities. Providing the results of economic evaluation for mass vaccination is of paramount importance for all stakeholders worldwide.enCOVID-19; Cost-benefit analysis; Cost-utility analysis; Vaccine; Value of statistical life[SDGs]SDG3bnt 162b 2; chadox1 ncov 19; mRNA-1273 vaccine; tozinameran; bnt 162 vaccine; ChAdOx1 COVID-19 vaccine; Article; asymptomatic coronavirus disease 2019; controlled study; coronavirus disease 2019; cost benefit analysis; cost effectiveness analysis; cost utility analysis; drug cost; drug efficacy; economic evaluation; education; health; high risk patient; hospitalization; human; major clinical study; Markov decision process; mass immunization; Monte Carlo method; outcome assessment; oxygenation; productivity; vaccination; Cost-Benefit Analysis; COVID-19; COVID-19 Vaccines; Humans; Mass Vaccination; SARS-CoV-2; Vaccinationjournal article10.1016/j.jfma.2021.05.020341081192-s2.0-85107446452https://api.elsevier.com/content/abstract/scopus_id/85107446452